|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study显示文摘 | Olivier Rixe Ronald M Bukowski M Dror Michaelson George Wilding Gary R Hudes Oliver Bolte Robert J Motzer Paul Bycott Katherine F Liau James Freddo Peter C Trask Sinil Kim Brian I Rini | 2007 | Lancet Oncology2007，，： | 2 |
| 2 | Polyacrylic fibers显示文摘 | Gries T Rixe C Steffens M | 2002 | Chemical Fibers International2002，52，： | 1 |
| 3 | Oxaliplatin,tetraplatin,cisplatin and carboplatin:sepctrum of activity in drug resistant cell lines of the national cancer institutes anticancer drug screen panel显示文摘 | Ortuzar W Alvarez M | 1996 | Biochem Pharmacd1996，52，12： | 1 |
| 4 | Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug resistant cell lines and in the cell lines of the national cancer institute' s anticancer drug screen panel 显示文摘 | Rixe O Ortuzar W Alvarez M | 1996 | Biochem Pharmacol1996，52，12： | 1 |
| 5 | Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy:results of the ECHO study显示文摘 | Zitt E Rix M Ure(n)a Torres P | | 0，，： | 1 |
| 6 | Polyacrylic fibers 显示文摘 | Gries T Rixe C Steffens M | 2002 | Chem Fibers Int2002，52，4： | 1 |
| 7 | Oxaliplatin,tetraplatin,cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel显示文摘 | RIXE O ORTUZAR W ALVAREZ M | 1996 | Biochem Pharmacol1996，52，12： | 1 |
| 8 | Oxaliplatin,tetraplatin,cisplatin and carboplatin:spectrum of activity in drug-resistant cell lines of the National Cancer Institute's Anticancer Drug Screen Panel显示文摘 | Rixe O Ortuzar W Alvarez M | 1996 | Bioehem Pharmaeol1996，52，12： | 1 |
| 9 | Efficacy and tolerability ofsevelamer carbonate in hyperphosphatemic patients who have chro-nic kidney disease and are not on dialysis显示文摘 | Ketteler M Rix M Fan S | 2008 | Clin J Am SocNephrol2008，3，4： | 1 |
| 10 | Oxaliplatin,tetralatin, cisplatin, and carboplatin: spectrum of activity in drug resistant cell lines and in the cell lines of the nation cancer institute's anticancer drug screen panel 显示文摘 | Rixe O Ortuzar W Alvarez M | 1996 | Biochem Pharmacol1996，52，12： | 1 |
| 11 | The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2- targeted microbubbles (BR55)显示文摘 | Bzyl J Palmowski M Rix A | 2013 | Eur Radiol2013，23，： | 1 |
| 12 | Oxaliplatin, tetraplatin, cisplatin in drug-resistant cell lines of the National cancer Institute, Anticancer Drug Screen panel显示文摘 | Ortuzar W Alvarez M | 1996 | Bioehem Pharmarol1996，52，： | 1 |
| 13 | GEMS:galaxy evolution from morphologies and SEDs显示文摘 | Rix H W Barden M Beckwith S V W | 2004 | The Astrophysical Journal Supplement Series2004，152，： | 1 |
| 14 | Stigmatization of people with mental illness显示文摘 | Crisp A H Gelder M C Rix S | 2000 | Br J Psychiatry2000，177，3： | 1 |
| 15 | Oxaliplatin,tetraplatin,cisplatin,and carboplat in:spectrum of activity in drug resistant cell lines and in the cell lines of the national cancer institute′s anticancer drug screen panel显示文摘 | Rixe O Ortuzar W Alvarez M | 1996 | Biochem Pharmacol1996，52，12： | 1 |
| 16 | Oxaliplatin,tetraplatin, cisplatin, and carboplatin: spectrum of activity indrug-resistant cell lines and in the cell lines of the NationalCancer Institute's Anticancer Drug Screen Panel 显示文摘 | RIXE 0 ORTUZAR W ALVAREZ M | 1996 | Biochem Pharmacol1996，52，12： | 1 |
| 17 | Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrunm of activity in drugresistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel显示文摘 | Rixe O Ortuzar W Alvarez M | 1996 | Biochem Pharmacol1996，52，12： | 1 |
| 18 | Impact of peripheral neuropathy on bone density in patients withtype 1 diabetes显示文摘 | Rix M Andreassen H Eskildsen P | 1999 | Diabetes Care1999，22，5： | 1 |
| 19 | Oxaliplatin,tetraplain,cisplatin and carboplatin:spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute,s Anti-cancer Drug Screen panel显示文摘 | Rixe O Ortuzar W Alvarez M | 1996 | Biochem Pharmacol1996，52，12： | 1 |
| 20 | Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis 显示文摘 | Ketteler M Rix M Fan S | 2008 | Clin J Am Soc Nephrol2008，3，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员